20-year follow-up of academic EORTC boost no-boost trial earns Best Abstract at ECC 2015

(European Organisation for Research and Treatment of Cancer) Results of a 20-year follow-up of the academic EORTC 22881-10882 boost no-boost trial presented as a 'Best Abstract' at the European Cancer Congress 2015 in Vienna show that young age, high-grade invasive tumor, and the presence of associated ductal carcinoma in situ were all factors increasing the local recurrence rate.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news